Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-969
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABBV-969 is an investigational antibody-drug conjugate (ADC) being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a first-in-class dual-targeting drug conjugate that targets two tumor-associated antigens highly expressed in mCRPC—prostate-specific membrane antigen (PSMA) and six transmembrane epithelial antigen of the prostate 1 (STEAP1). The ADC delivers a topoisomerase 1 inhibitor payload to cancer cells expressing these antigens. By targeting both PSMA and STEAP1, ABBV-969 aims to address the heterogeneity of antigen expression in advanced prostate cancer, potentially improving efficacy over single-target approaches. The drug is currently being evaluated as monotherapy in Phase 1 clinical trials to assess its safety, pharmacokinetics, and preliminary efficacy[1][2][4][6].
- Other names
- anti-PSMA/STEAP1 antibody-drug conjugate ABBV-969
02
Targets
TOP1 (DNA Topoisomerase I)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on ABBV-969.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-969.